TABLE 1.
Characteristics of the participants included in genome-wide association analyses (with both nonmissing genotype and phenotype data)
| Sample characteristic | ADVANCE control (up to 311) | ADVANCE cases (up to 275) | ARIC (up to 8,127) | CHS (up to 3,262) | FHS (up to 2,432) | GeneSTAR (up to 1,789) | GENOA (up to 1,208) | NFBC (up to 4,757) |
|---|---|---|---|---|---|---|---|---|
| % Females | 59 | 59 | 53 | 61 | 55 | 52 | 55 | 52 |
| % Diabetic* | 2.5 | 27 | 8 | 12 | 5 | 9 | 10 | 1 |
| % Smoking† | 32.8 | 63.3 | 25 | 11 | 29 | 23 | 14 | 30 |
| Age (years) | ||||||||
| Men | 40 ± 3 | 42 ± 4 | 55 ± 6 | 73 ± 6 | 50 ± 13 | 47 ± 13 | 56 ± 11 | 31 ± 1 |
| Women | 48 ± 5 | 52 ± 4 | 54 ± 6 | 72 ± 5 | 51 ± 13 | 47 ± 13 | 55 ± 11 | 31 ± 1 |
| BMI (kg/m2) | ||||||||
| Men | 27 ± 5 | 31 ± 6 | 27 ± 4 | 26 ± 4 | 28 ± 4 | 29 ± 5 | 30 ± 5 | 25 ± 4 |
| Women | 26 ± 6 | 31 ± 8 | 27 ± 6 | 26 ± 5 | 27 ± 6 | 29 ± 7 | 31 ± 7 | 24 ± 5 |
| Waist circumference (cm) | ||||||||
| Men | 93 ± 12 | 102 ± 14 | 100 ± 10 | 98 ± 10 | 100 ± 12 | 101 ± 14 | 104 ± 12 | 89 ± 10 |
| Women | 79 ± 13 | 94 ± 19 | 93 ± 15 | 90 ± 14 | 94 ± 16 | 94 ± 17 | 96 ± 17 | 79 ± 12 |
| HDL cholesterol (mg/dL) | ||||||||
| Men | 44 ± 11 | 40 ± 10 | 43 ± 12 | 48 ± 13 | 43 ± 11 | 45 ± 13 | 45 ± 13 | 55 ± 13 |
| Women | 62 ± 14 | 51 ± 16 | 57 ± 17 | 60 ± 16 | 56 ± 15 | 57 ± 15 | 57 ± 17 | 66 ± 15 |
| Triglycerides (mg/dL) | ||||||||
| Men | 151 ± 224 | 184 ± 165 | 147 ± 100 | 138 ± 78 | 163 ± 113 | 160 ± 97 | 194 ± 107 | 119 ± 75 |
| Women | 97 ± 69 | 162 ± 145 | 128 ± 81 | 141 ± 74 | 138 ± 87 | 133 ± 79 | 188 ± 102 | 94 ± 52 |
| Fasting glucose (mg/dL) | ||||||||
| Men | 86 ± 11 | 104 ± 43 | 107 ± 27 | 111 ± 31 | 102 ± 29 | 99 ± 27 | 103 ± 32 | 93 ± 11 |
| Women | 88 ± 11 | 95 ± 18 | 102 ± 28 | 105 ± 27 | 95 ± 22 | 92 ± 21 | 96 ± 27 | 88 ± 11 |
| SBP (mmHg) | ||||||||
| Men | 117 ± 11 | 114 ± 12 | 120 ± 16 | 135 ± 21 | 119 ± 15 | 126 ± 16 | 134 ± 17 | 130 ± 13 |
| Women | 109 ± 13 | 118 ± 20 | 117 ± 18 | 135 ± 21 | 114 ± 18 | 121 ± 17 | 132 ± 17 | 120 ± 12 |
| DBP (mmHg) | ||||||||
| Men | 78 ± 10 | 73 ± 10 | 74 ± 10 | 72 ± 11 | 72 ± 9 | 80 ± 11 | 81 ± 10 | 80 ± 11 |
| Women | 70 ± 9 | 70 ± 10 | 70 ± 10 | 69 ± 11 | 67 ± 10 | 76 ± 10 | 77 ± 9 | 75 ± 11 |
| % Antihyperlipidemic meds. use | 4 | 81 | 3 | 4 | 10 | 15 | 17 | 0 |
| % Antihypertensive meds. use | 7 | 84 | 20 | 35 | 3 | 22 | 65 | 0.6 |
| % Antiglycemic meds. use‡ | 1.3 | 24 | 3.2 | 5 | 0.2 | 4.3 | 6.9 | 0.6 |
| MetS prevalence (%) | 13.7 | 55.2 | 37.3 | 41.7 | 29.7 | 34.3 | 55.4 | 9.1 |
Values are means ± SD for each quantitative variable and where available split by male/female grouping. Meds., medication.
*Definition of type 2 diabetes: fasting blood glucose >126 mg/dL or antiglycemic medication use.
†Smoking: current smoking.
‡Antiglycemic meds. use: oral hypoglycemic agents or insulin.